Epoetin-alpha: Preserving kidney function via attenuation of polymorphonuclear leukocyte priming

Israel Medical Association Journal

Volumn 10, Issue 4, 2008, Pages 266-272

  Kristal, Batya ^a,b   Shurtz Swirski, Revital ^a   Tanhilevski, Olga ^a   Shapiro, Galina ^a   Shkolnik, Galina ^a   Chezar, Judith ^a   Snitkovsky, Tamara ^a   Cohen Mazor, Meital ^a,b   Sela, Shifra ^a,b  

^a WESTERN GALILEE HOSPITAL   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Epoetin alpha; Erythropoietin receptor; Inflammation; Oxidative stress; Polymorphonuclear leukocyte priming

Indexed keywords

ALKALINE PHOSPHATASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CARBONATE; CALCIUM CHANNEL BLOCKING AGENT; ERYTHROPOIETIN RECEPTOR; FERROUS SULFATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; SUPEROXIDE;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG EFFICACY; ENZYME RELEASE; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; GLOMERULUS FILTRATION RATE; HUMAN; IN VIVO STUDY; LEUKOCYTE COUNT; MALE; NEPHRITIS; NEUTROPHIL COUNT; PROTEIN EXPRESSION; RENAL PROTECTION; TREATMENT DURATION;

AGED; ANEMIA; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; GLOMERULAR FILTRATION RATE; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; NEUTROPHILS; OXIDATIVE STRESS; RECEPTORS, ERYTHROPOIETIN; SEVERITY OF ILLNESS INDEX; SUPEROXIDE DISMUTASE;

EID: 43249088584     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005;45:39-47.
2. Rossert J, McClellan WM, Roger SD, Verbeelen DL. Epoetin treatment: what are the arguments to expect a beneficial effect on renal disease progression? Nephrol Dial Transplant 2002;17:359-62.
3. Sela S, Shurtz-Swirski R, Cohen-Mazor M, et al. The primed peripheral polymorphonuclear leukocyte - a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol 2005;16:2431-8.
4. Kristal B, Shurtz-Swirski R, Shasha SM, et al. Interaction between erythropoietin and peripheral polymorphonuclear leukocytes in hemodialysis patients. Nephron. 1999;81:406-13.
5. Shurtz-Swirski R, Kristal B, Shasha SM, et al. Interaction between erythropoietin and peripheral polymorphonuclear leukocytes in continuous ambulatory dialysis patients. Nephron 2002;91:759-61.
6. Sela S, Shurtz-Swirski R, Sharoh R, et al. The polymorphonuclear leukocyte - a new target for erythropoietin. Nephron 2001;88: 205-10.
7. Vervoort G, Willems HL, Werzels JF. Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: Validity of a new (MDRD) prediction equation. Nephrol Dial Transplant 2002;17:1909-13.
8. Kristal B, Shurtz-Swirski R, Shapiro G, et al. Participation of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation in patients with essential hypertension. Am J Hypertens 1998;11:921-8.
9. Shen K, DeLano FA, Zweifach BW, Schmid-Schonbein GW. Circulating leukocyte counts, activation and degranulation in Dahl hypertensive Rats. Circulation Res 1995;76:276-83.
10. Izumi M, Ishikawa J, Takeshita A, Maekawa M. Inceased serum alkaline phosphatase activity originating from neutrophilic leukocytes. Clin Nephrol 2005;51:1751-2.
11. Kalantar-Zadeh K, Stenvinkel P, Pillon L, Kopple JD. Inflammation and nutrition in renal insufficiency. Adv Ren Replace Ther 2003;10: 155-69.
12. Fait V, Sela S, Ophir E, et al. Peripheral polymorphonuclear leukocyte priming contributes to oxidative stress in early pregnancy. J Soc Gynecol Investig 2005;12:46-9.
13. Sela S, Shurtz-Swirski R, Awad J, et al. The involvement of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation among cigarette smokers. IMAJ 2002;4:1015-19.
14. Shurtz-Swirski R, Sela S, Herskovits AT, et al. Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients. Diabetes Care 2001;24;104-10.
15. Mazor R, Shurtz-Swirski R, Farah R, et al. Primed polymorphonuclear leukocytes constitute, a possible link between inflammation and oxidative stress in hyperlipidemic patients. Atherosclerosis 2008; 197:937-43.
16. Finidori J. Regulators of growth hormone signaling. Vitam Horm 2000;59:71-47.
17. Morath C, Dechow C, Lehrke I, et al. Effects of retinoids on the TGF-beta system and extracellular matrix in experimental glomerulonephritis. J Am Soc Nephrol 2001;12:2300-9.
18. Chade AR, Rodriguez-Porcel M, Grande JP, et al. Distinct renal injury in early atherosclerosis and renovascular disease. Circulation 2002;106:1165-71.
19. Erlinger TP, Tarver-Carr ME, Powe NR, et al. Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults. Am J Kidney Dis 2003;42:256-63.
20. Westenfelder C, Biddle DL, Baranowski RL. Human, rat and mouse kddney cells express functional erythropoietin receptors. Kidney Int 1999;55:808-20.
21. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001;16:307-12.
22. Dean BB, Dylan M, Gano A Jr, Knight K, Ofman JJ, Levine BS. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005;21:981-7.
23. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141-6.
24. Siamopoulos KC, Gouva C, Katopodis KP, et al. Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD. Am J Kidney Dis 2006;48:242-9.
25. Rossert J, Levin A, Roger SD, et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 2006;47:738-50.